We are live on ! Find out more
TEVA icon

Teva Pharmaceuticals
TEVA

429 hedge funds and large institutions have $5.14B invested in Teva Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 124 increasing their positions, 142 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

6% less call options, than puts

Call options by funds: $296M | Put options by funds: $315M

3% less funds holding

Funds holding: 440 → 429 (-11)

2.99% less ownership

Funds ownership: 50.84% → 47.85% (-3%)

7% less capital invested

Capital invested by funds: $5.55B → $5.14B (-$411M)

13% less first-time investments, than exits

New positions opened: 35 | Existing positions closed: 40

13% less repeat investments, than reductions

Existing positions increased: 124 | Existing positions reduced: 142

Holders
429
Holders Change
-11
Holders Change %
-2.5%
% of All Funds
7.51%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
35
Increased
124
Reduced
142
Closed
40
Calls
$296M
Puts
$315M
Net Calls
-$18.9M
Net Calls Change
+$23.5M

Top Buyers

Rank Fund Capital Flow
1
MMH
Menora Mivtachim Holdings
Israel
+$30.1M
2
BMO
Beck Mack & Oliver
New York
+$27.3M
3
PF
Phoenix Financial
Israel
+$24.5M
4
Jane Street
Jane Street
New York
+$24.4M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$24.3M

Top Sellers

Rank Fund Capital Flow
1
Capital World Investors
Capital World Investors
California
-$404M
2
Capital Research Global Investors
Capital Research Global Investors
California
-$35.4M
3
Norges Bank
Norges Bank
Norway
-$21.9M
4
Citigroup
Citigroup
New York
-$17.5M
5
JP Morgan Chase
JP Morgan Chase
New York
-$12M
Name Holding Trade Value Shares
Change 		Change in
Stake
CFB
376
Cullen/Frost Bankers
Texas
$3K – – –
GWS
377
Glassman Wealth Services
Virginia
$3K +$459 +49 +20%
EIP
378
Ellis Investment Partners
Pennsylvania
$3K +$496 +53 +15%
SCA
379
Stonebridge Capital Advisors
Minnesota
$2K -$14.9K -1,595 -89%
ATC
380
Adirondack Trust Company
New York
$2K -$1.25K -134 -40%
BAM
381
Bellevue Asset Management
Washington
$2K – – –
CAL
382
Capital Analysts LLC
Pennsylvania
$2K – – –
CCA
383
Column Capital Advisors
Indiana
$2K – – –
CAM
384
Costello Asset Management
Pennsylvania
$2K – – –
EWA
385
Evolution Wealth Advisors
Florida
$2K – – –
FRA
386
Front Row Advisors
California
$2K – – –
GCM
387
Gables Capital Management
Florida
$2K – – –
GI
388
Gradient Investments
Minnesota
$2K – – –
JWA
389
JFS Wealth Advisors
Pennsylvania
$2K – – –
JMF
390
Johnson Midwest Financial
Iowa
$2K – – –
OIA
391
Optimum Investment Advisors
Illinois
$2K – – –
PWMG
392
Prestige Wealth Management Group
New Jersey
$2K – – –
TWA
393
TCI Wealth Advisors
Arizona
$2K – – –
TCWA
394
Ten Capital Wealth Advisors
Washington
$2K – – –
TI
395
Truehand Inc
New Hampshire
$2K – – –
TFGT
396
TS Financial Group (TSFG)
Illinois
$2K – – –
WB
397
Webster Bank
Connecticut
$2K – – –
GRP
398
Global Retirement Partners
California
$2K +$1.21K +129 +263%
HWA
399
Heritage Wealth Advisors
Virginia
$1.46K – – –
KFS
400
Kelly Financial Services
Massachusetts
$1.36K -$11.7K -1,246 -90%
14 15
16
17 18

TEVA Hedge Fund Activity: Q3 2021 in Review

429 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q3 2021, worth a combined $5.14B — down 7.4% from $5.55B a quarter earlier.

Sellers outnumbered buyers: 40 funds closed out of TEVA and 35 opened new positions — a net loss of 5 holders — while 142 trimmed existing stakes and 124 added.

The largest buyer was Menora Mivtachim Holdings, adding an estimated $30.1M. The largest seller was Capital World Investors, cutting an estimated $404M.

  • 429 institutional investors held Teva Pharmaceuticals (TEVA) as of Q3 2021, down from 440 in Q2 2021.
  • Funds reported $5.14B of Teva Pharmaceuticals stock for Q3 2021, down 7.4% quarter-over-quarter.
  • 35 funds opened new Teva Pharmaceuticals positions in Q3 2021 and 40 closed out, a net change of -5 holders.
  • The largest Teva Pharmaceuticals buyer in Q3 2021 was Menora Mivtachim Holdings, an estimated $30.1M added.
  • The largest Teva Pharmaceuticals seller in Q3 2021 was Capital World Investors, an estimated $404M sold.

Based on aggregated 13F filings for Q3 2021.